

**Ovoca Bio plc**

("Ovoca" or the "Company")

**Result of AGM**

Dublin, Ireland, 18 December 2024 - Ovoca Bio plc, a biopharmaceutical company with a focus on women's health, announces that each of the resolutions proposed at its Annual General Meeting held earlier today were duly passed by shareholders.

The full text of each resolution was set out in the Notice of Annual General Meeting circulated to shareholders on 18 November 2024.

**End**

For further information:

**Ovoca Bio plc**

Tim McCutcheon (Chief Executive Officer)  
Tel +353 1 661 9819  
info@ovocabio.com

**Davy (Nominated Adviser, Euronext Growth Listing Sponsor and Broker)**

Ivan Murphy / Daragh O'Reilly  
Tel: +353 1 679 6363

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

RAGBRBDDCDBDGSI